186 related articles for article (PubMed ID: 18385505)
1. Telbivudine versus lamivudine in patients with chronic hepatitis B.
Tillmann HL; McHutchison JG
N Engl J Med; 2008 Apr; 358(14):1517; author reply 1517-8. PubMed ID: 18385505
[No Abstract] [Full Text] [Related]
2. Treatment of chronic hepatitis B with telbivudine: wise hepatologists needed in hepatitis B endemic countries where treatment options are limited.
Yurdaydin C; Akarca US
Liver Int; 2011 May; 31(5):589-91. PubMed ID: 21457431
[No Abstract] [Full Text] [Related]
3. Telbivudine versus lamivudine in patients with chronic hepatitis B.
Lai CL; Gane E; Liaw YF; Hsu CW; Thongsawat S; Wang Y; Chen Y; Heathcote EJ; Rasenack J; Bzowej N; Naoumov NV; Di Bisceglie AM; Zeuzem S; Moon YM; Goodman Z; Chao G; Constance BF; Brown NA;
N Engl J Med; 2007 Dec; 357(25):2576-88. PubMed ID: 18094378
[TBL] [Abstract][Full Text] [Related]
4. [Telbivudine in the treatment of the chronic B hepatitis].
Butà MA
Gastroenterol Hepatol; 2008 Apr; 31(4):258-63. PubMed ID: 18405491
[No Abstract] [Full Text] [Related]
5. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
Hou J; Yin YK; Xu D; Tan D; Niu J; Zhou X; Wang Y; Zhu L; He Y; Ren H; Wan M; Chen C; Wu S; Chen Y; Xu J; Wang Q; Wei L; Chao G; Constance BF; Harb G; Brown NA; Jia J
Hepatology; 2008 Feb; 47(2):447-54. PubMed ID: 18080339
[TBL] [Abstract][Full Text] [Related]
6. [The efficacy and safety of telbivudine in korean patients with chronic hepatitis B].
Moon YM; Hwang SG; Kim BS; Rim KS; Cho M; Kim DJ; Han JY; Kim YS; Choi HS; Ahn SH
Korean J Hepatol; 2007 Dec; 13(4):503-12. PubMed ID: 18159148
[TBL] [Abstract][Full Text] [Related]
7. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.
Liaw YF; Gane E; Leung N; Zeuzem S; Wang Y; Lai CL; Heathcote EJ; Manns M; Bzowej N; Niu J; Han SH; Hwang SG; Cakaloglu Y; Tong MJ; Papatheodoridis G; Chen Y; Brown NA; Albanis E; Galil K; Naoumov NV;
Gastroenterology; 2009 Feb; 136(2):486-95. PubMed ID: 19027013
[TBL] [Abstract][Full Text] [Related]
8. A review of telbivudine for the management of chronic hepatitis B virus infection.
Lui YY; Chan HL
Expert Opin Drug Metab Toxicol; 2008 Oct; 4(10):1351-61. PubMed ID: 18798704
[TBL] [Abstract][Full Text] [Related]
9. [Telbivudine treatment on cirrhosis resulting from chronic hepatitis B].
Liang J; Han T; Xiao SX
Zhonghua Gan Zang Bing Za Zhi; 2009 Jan; 17(1):24-7. PubMed ID: 19203447
[TBL] [Abstract][Full Text] [Related]
10. Summaries for patients. Antiviral therapy for chronic hepatitis B.
Ann Intern Med; 2007 Dec; 147(11):I16. PubMed ID: 17909200
[No Abstract] [Full Text] [Related]
11. Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine.
Safadi R; Xie Q; Chen Y; Yin YK; Wei L; Hwang SG; Zuckerman E; Jia JD; Lopez P
Liver Int; 2011 May; 31(5):667-75. PubMed ID: 21040410
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of telbivudine versus lamivudine for chronic hepatitis B.
Wiens A; Venson R; Correr CJ; Pontarolo R
Braz J Infect Dis; 2011; 15(3):225-30. PubMed ID: 21670922
[TBL] [Abstract][Full Text] [Related]
13. Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome.
Seto WK; Lai CL; Fung J; Wong DK; Yuen JC; Hung IF; Yuen MF
J Hepatol; 2011 Sep; 55(3):522-528. PubMed ID: 21147187
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus resistance to antiviral drugs: where are we going?
Zoulim F
Liver Int; 2011 Jan; 31 Suppl 1():111-6. PubMed ID: 21205147
[TBL] [Abstract][Full Text] [Related]
15. [The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52].
Jia JD; Hou JL; Yin YK; Xu DZ; Tan DM; Niu JQ; Zhou XQ; Wang YM; Zhu LM; He YW; Ren H; Wan MB; Chen CW; Wu SM; Chen YG; Xu JZ; Wang QH; Wei L; Ma H
Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):342-5. PubMed ID: 17524265
[TBL] [Abstract][Full Text] [Related]
16. New treatment of chronic hepatitis B.
Lok AS
Semin Liver Dis; 2004; 24 Suppl 1():77-82. PubMed ID: 15192805
[TBL] [Abstract][Full Text] [Related]
17. Current status of nucleoside antivirals in chronic hepatitis B.
Duong A; Mousa SA
Drugs Today (Barc); 2009 Oct; 45(10):751-61. PubMed ID: 20069139
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B: a "GLOBAL" health challenge.
Fontana RJ
Gastroenterology; 2009 Feb; 136(2):389-92. PubMed ID: 19109963
[No Abstract] [Full Text] [Related]
19. Drug profile: telbivudine (Tyzeka).
Pham PA; Thio C
Hopkins HIV Rep; 2007 Jan; 19(1):7, 10. PubMed ID: 17569169
[No Abstract] [Full Text] [Related]
20. Complementarity-determining region 3 size spectratypes of T cell receptor beta chains in CD8+ T cells following antiviral treatment of chronic hepatitis B.
Ma SW; Li YY; Zhang GW; Huang X; Sun J; Li C; Abbott WG; Hou JL
Antimicrob Agents Chemother; 2011 Feb; 55(2):888-94. PubMed ID: 21098256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
